Sensei Biotherapeutics’ (FTH) Buy Rating Reiterated at BTIG Research

Sensei Biotherapeutics (NASDAQ:FTH)‘s stock had its “buy” rating restated by investment analysts at BTIG Research in a research report issued on Tuesday, Benzinga reports. They currently have a $55.00 price objective on the stock. BTIG Research‘s price objective indicates a potential upside of 226.80% from the stock’s previous close.

Several other equities research analysts also recently weighed in on FTH. William Blair started coverage on Sensei Biotherapeutics in a report on Friday, October 16th. They issued an “outperform” rating on the stock. Guggenheim assumed coverage on Sensei Biotherapeutics in a report on Wednesday, September 16th. They set a “buy” rating and a $70.00 price objective for the company. JonesTrading began coverage on Sensei Biotherapeutics in a report on Tuesday, August 4th. They set a “buy” rating and a $55.00 price objective for the company. Raymond James Financial assumed coverage on Sensei Biotherapeutics in a research report on Friday, July 31st. They issued an “outperform” rating and a $56.00 price objective on the stock. Finally, Oppenheimer initiated coverage on shares of Sensei Biotherapeutics in a research note on Tuesday, July 28th. They set an “outperform” rating and a $60.00 target price for the company. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Sensei Biotherapeutics presently has a consensus rating of “Buy” and a consensus target price of $56.25.

Sensei Biotherapeutics Price Performance

Sensei Biotherapeutics stock opened at $16.83 on Tuesday. The stock has a market cap of $434.89 million, a price-to-earnings ratio of -0.12 and a beta of -0.29. Sensei Biotherapeutics has a 1-year low of $7.45 and a 1-year high of $42.14. The stock has a 50-day moving average price of $29.91.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($5.04) by $2.20. On average, equities analysts predict that Sensei Biotherapeutics will post -13.69 EPS for the current year.

Institutional Investors Weigh In On Sensei Biotherapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of FTH. Citadel Advisors LLC purchased a new position in shares of Sensei Biotherapeutics during the second quarter valued at $307,000. Renaissance Technologies LLC raised its holdings in shares of Sensei Biotherapeutics by 178.2% in the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after acquiring an additional 20,525 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after acquiring an additional 32,719 shares in the last quarter. Stempoint Capital LP purchased a new stake in Sensei Biotherapeutics in the first quarter worth about $4,188,000. Finally, Alyeska Investment Group L.P. purchased a new stake in Sensei Biotherapeutics in the second quarter worth about $3,610,000. 10.50% of the stock is owned by institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.